www.jdrf.org Open in urlscan Pro
104.196.154.174  Public Scan

Form analysis
2 forms found in the DOM

<form>
  <div class="spirit-form__field-group spirit-form__input spirit-form__input--with-icon" role="combobox" aria-expanded="false" aria-haspopup="listbox" aria-labelledby="downshift-0-label"><label for="jdrf-global-header-search" id="downshift-0-label"
      class="spirit-form__label spirit-form__label-accessible-text">Search</label>
    <div class="spirit-form__input-icon-wrap -left"><svg xmlns="http://www.w3.org/2000/svg" class="spirit-icon spirit-form__input-icon" viewBox="0 0 24 24">
        <path d="M11,20c-5,0-9-4-9-9c0-5,4-9,9-9c5,0,9,4,9,9C20,16,16,20,11,20z M11,4c-3.9,0-7,3.1-7,7c0,3.9,3.1,7,7,7c3.9,0,7-3.1,7-7 C18,7.1,14.9,4,11,4z"></path>
        <path d="M21,22c-0.3,0-0.5-0.1-0.7-0.3l-4.3-4.3c-0.4-0.4-0.4-1,0-1.4s1-0.4,1.4,0l4.3,4.3c0.4,0.4,0.4,1,0,1.4 C21.5,21.9,21.3,22,21,22z"></path>
      </svg></div><input aria-autocomplete="list" aria-labelledby="downshift-0-label" autocomplete="off" id="jdrf-global-header-search" placeholder="Search" class="spirit-form__input-field" value=""><input type="submit"
      class="spirit-form__label-accessible-text" value="Submit">
  </div>
</form>

POST form/processor

<form class="spirit-form" method="post" action="form/processor">
  <div class="spirit-form__field-group">
    <label class="spirit-form__label" for="full-form-email"> Email <abbr class="spirit-form__label-required-indicator" title="This field is required." aria-hidden="true">*</abbr>
      <span class="spirit-form__label-accessible-text">Required Field.</span>
    </label>
    <div class="spirit-form__input">
      <input class="spirit-form__input-field required" type="email" id="full-form-email" placeholder="Enter your address">
    </div>
  </div>
</form>

Text Content

For screen-reader mode - click the first button of the websiteAccessibility
Screen-Reader Guide, Feedback, and Issue Reporting
Skip to content
JDRF
{{logo_image_dark}}
Search

Close Navigation Menu
 * Login
 * My Events / Fundraisers
    * My Events / Fundraisers
    * My Account
    * Logout

 * Home
 * Our Impact
    * Overview
   
    * Research
      * Overview
      * Cures
      * Improving Lives
      * Funded Research
      * Early Career Scientists
      * Inside the Lab
      * Meet the Scientists
      * Centers of Excellence
   
    * Advocacy
      * Overview
      * Advocacy Agenda
      * Federal Funding
      * Healthcare Principles
      * Insulin Access and Innovation
      * Medicare Coverage
      * Special Diabetes Program
      * T1D Outcomes
   
    * Our Impact
    * Research News
    * Clinical Trials

 * T1D Resources
    * Overview
   
    * Newly Diagnosed
      * Overview
      * Support for Children
      * Support for Teens
      * Support for Adults
      * Putting Together Your Support Team
      * No Limits Speaker Series
   
    * T1D Basics
      * Overview
      * Symptoms
      * Causes
      * Diagnosis
      * Treatments
      * Insulin
      * FAQ
   
    * Life With T1D
      * Overview
      * Insurance
      * School
      * Complications
      * Exercise
      * Mental Health
      * Food and Diet
      * Pregnancy
      * Parenting and Relationships
      * View All
   
    * Daily Management
      * Overview
      * Checking Blood Sugar
      * Administering Insulin
      * Insulin Pump Choice
      * Using Blood Sugar Monitors
      * Carb Counting Tips
      * Better Diabetes Management
   
    * T1Detect
    * Personal Support
    * Clinical Trials
    * For Healthcare Professionals
    * Recursos en Español

 * Community
    * Overview
   
    * JDRF Near You
      * Overview
      * Volunteer
      * Events and Groups
      * Find a Chapter
   
    * TypeOneNation
      * Overview
      * Online Forum
      * TypeOneNation Summits
      * Get Personal Support
   
    * Take Action
      * Overview
      * NDAM 2022
      * Coverage 2 Control
      * Children’s Congress
      * Promise to Remember Me
      * Advocates in Action Council
   
    * Partners
      * Overview
      * Celebrity Ambassadors
      * Corporate Partners
      * Shop and Give Back
   
    * National Volunteer Week 2023

 * Calendar
 * Fundraising
    * Overview
   
    * Events
      * Overview
      * Walk
      * Ride
      * Run / Challenge
      * Gala
      * Golf
      * Create Your Own
      * JDRF Game2Give
      * View All
   
    * Giving
      * Overview
      * Find a Fundraiser
      * Tribute
      * Memorial
      * Leadership Giving
      * Monthly Giving
      * Planned Giving
      * Workplace Giving
      * View All
   
    * Participant Center
    * Start a Fundraiser

 * More
    * Overview
   
    * About Us
      * Overview
      * Financials
      * Leadership
      * Global Mission Board
      * International Affiliates
      * T1D Fund
      * For Researchers (Grant Center)
      * Diversity & Inclusion
   
    * For Media
      * Overview
      * Press Releases
      * JDRF in the News
   
    * Careers
    * Blog
    * JDRF Logo Usage
    * Contact Us

 * Donate
    * Donate now
   
    * Ways to Give
      * Tribute
      * Memorial
      * By Check or Phone
      * Planned Giving
      * Workplace Giving
      * View All
   
    * Fundraising Events
      * Find a Fundraiser
      * Ways to Fundraise

 * Login
 * My Events / Fundraisers
    * My Events / Fundraisers
    * My Account
    * Logout

Toggle SearchToggle Navigation Menu



TOP TYPE 1 DIABETES ADVANCES OF FISCAL YEAR 2023 

Published June 12, 2023 in Advocacy, Artificial pancreas, Beta cell
regeneration, Beta cell replacement, Clinical trials, Complications, Continuous
glucose monitors, Encapsulation, FDA Regulatory, Glucose control, Immune
Therapies, Prevention, Research, Research News

 * Share on Facebook
 * Tweet on Twitter
   



JDRF’s vision is a world without type 1 diabetes (T1D)  and in the past fiscal
year, through many top type 1 diabetes advances, we’ve made incredible progress
toward that goal.  

Your support of our efforts is inseparable from the top type 1 diabetes advances
we’ve seen in accelerating cures, improving lives, and advocacy wins for people
with T1D and their loved ones. 

As we approach the end of fiscal year 2023 (FY23), let’s highlight the many  top
type 1 diabetes advances we’ve seen.


TOP TYPE 1 DIABETES ADVANCE 1: FIRST T1D DISEASE-MODIFYING THERAPY  

In a historic moment for T1D—and one that JDRF had a hand in from the beginning,
supporting research from the 1980s on—the U.S. Food and Drug Administration
(FDA) approved Tzield™ (teplizumab-mzwv) for use in delaying the onset of
clinical disease in at-risk individuals aged 8+. 

For the first time in history, Tzield will treat the autoimmune process behind
T1D, not the symptoms, altering the course of the disease.  

Among our top type 1 diabetes advances, this is the first disease-modifying
therapy—treatments that can slow, halt, or reverse the course of the disease—for
T1D to be approved, but it won’t be the last.  

Additionally, months after Tzield’s FDA approval, Sanofi acquired Provention
Bio, the manufacturer of Tzield.  

The acquisition brings the first T1D disease-modifying therapy available in the
U.S. into the portfolio of a global leading pharmaceutical company, representing
an endorsement of the potential of these types of therapies and, we hope, the
opportunity to bring this life-changing therapy and others in the pipeline to
more people faster.  

Tzield and breakthroughs like it put us on the pathway to finding cures and, one
day, preventing T1D entirely. 


TOP TYPE 1 DIABETES ADVANCE 2: A BLOOD PRESSURE DRUG PRESERVES BETA CELL
FUNCTION  

A JDRF-funded study found that children and teens newly diagnosed with T1D who
took verapamil—a drug already approved to treat high blood pressure—were making
more insulin one year after diagnosis than those on placebo. In other words, in
the children and teens who took verapamil, more beta cells were healthier one
year post T1D diagnosis than those in the children and teens who took the
placebo. 

This was the second trial that found the drug can preserve beta cells in the
newly onset period.  

Additional studies may be needed to further validate the results, as well as
identify all benefits and potential side effects of the drug. JDRF has the
strategy to answer these and other questions. 

The finding brings us closer to our goal of having numerous disease-modifying
therapies widely available for people with type 1 diabetes. 


TOP TYPE 1 DIABETES ADVANCE 3: AFFORDABLE INSULINS FOR EVERYONE 

JDRF and partnering organizations are supporting nonprofit pharmaceutical
manufacturer Civica Rx to produce biosimilar insulin that will cost no more than
$30 a vial/$55 a box of five pens, regardless of insurance status.  

One year after the Civica announcement, Eli Lilly, Novo Nordisk, and Sanofi all
announced reductions to the prices of their insulins—including the most used
insulins, such as Humalog, NovoLog, and Lantus.  

Another big win for insulin affordability was the $35 monthly out-of-pocket
co-pay cap for those on Medicare included in the Inflation Reduction Act that
JDRF fought hard to secure.  

In April, the Senate Diabetes Caucus Co-Chairs, Jeanne Shaheen (D-NH) and Susan
Collins (R-ME), introduced the INSULIN Act of 2023, another key step toward
achieving affordable insulin for all who need it.  

The bill seeks to limit out-of-pocket insulin costs by ensuring that people with
commercial insurance pay no more than $35 or 25 percent of the net price per
month for at least one insulin of each type and dosage form, and includes other
important provisions to help make insulin more affordable and accessible.  

You can contact your members of Congress and encourage them to support the
INSULIN Act of 2023.  


TOP TYPE 1 DIABETES ADVANCE 4: TURBO BOOSTING CELL THERAPIES  

JDRF is working to develop and deliver life-changing therapies that place
healthy, insulin-producing beta cells back into the bodies of people with T1D.
There was a lot of progress in FY23.  

Vertex, which previously acquired Semma Therapeutics, also acquired ViaCyte,
bringing together the leading companies developing stem cell-based therapies for
diabetes.  

Vertex is advancing a stem cell-derived islet replacement therapy for T1D. It’s
in human clinical trials and showing amazing results, with one participant being
off insulin entirely.  

Vertex also started a trial with a new product using encapsulated stem
cell-derived islets as replacement therapy, and is exploring gene-edited stem
cell-based therapies—both  with the goal of eliminating the need for
immunosuppressive drugs. 

Just this past April, Aspect Biosystems—an industry leader in 3D bioprinting
technology—and Novo Nordisk announced a partnership to expand the development of
a new class of treatments for diabetes and obesity, using Aspect’s bioprinting
technology and Novo Nordisk’s expertise in stem cell and cell therapy
development. 

The Aspect-Novo Nordisk partnership’s initial focus will be on developing
bioprinted therapies for transplant that would be designed to maintain normal
blood-sugar levels without the need for immunosuppression. This could represent
a transformative treatment for people living with T1D. 


APPROVED! NUMEROUS T1D MANAGEMENT TECHNOLOGIES

JDRF funds research to facilitate the development of new therapies and
technologies to make day-to-day life with T1D easier, safer, and healthier. In
the past year, we saw: 

Newly-Approved Artificial Pancreas (AP) Systems and Algorithms 

 * iLet® Insulin-Only Bionic Pancreas System for ages 6+  
 * Medtronic MiniMed™ 780G AP system for ages 7+ 
 * Tidepool Loop, an algorithm that will allow for interoperability of
   continuous glucose monitors (CGMs) and insulin pumps 

 Newly-Approved Continuous Glucose Monitoring (CGM) Systems  

 * Dexcom G7® CGM system for ages 2+ 


A NEW TOOL TO ACCURATELY DIAGNOSE TYPE 1 IN ADULTS 

Misdiagnosing adults with T1D as having T2D is an all-too-common problem that
can have tragic consequences. JDRF and IQVIA teamed up to develop an algorithm
using artificial intelligence to examine medical records and identify
individuals who were diagnosed with T2D but actually have T1D. This could be
used in real time to correct misdiagnoses, offering the potential for future
development into a clinical decision support tool. 


A FIRST-OF-ITS-KIND LIFESAVING TOOL: THE T1D INDEX  

JDRF and other T1D-related organizations launched the T1D Index, a
first-of-its-kind data simulation tool that offers the most accurate estimate of
T1D ever created. The Index measures and maps how many people live with this
condition in every country, the healthy years of life it takes from people
living with T1D, the number of people who would still be alive today if they
hadn’t died prematurely from T1D complications, and our global strategy to
reduce the impact of T1D. 

GO FORWARD 

Your partnership has been crucial to these advances and many more. On behalf of
our community, thank you for moving us forward and ever closer to a world
without T1D.  

We are excited for the top type 1 diabetes advances that fiscal year 2024 (FY24)
will bring! 

--------------------------------------------------------------------------------

READ PAST BLOGS ABOUT TOP TYPE 1 DIABETES ADVANCES: 

What We Can Be Proud of in 2022 

Celebrating the Best of 2021 

What We Can Be Proud Of in 2020 

Top 10 T1D Breakthroughs of 2019 

By JDRF

 * Share on Facebook
 * Tweet on Twitter
   

JDRF


READ NEXT


 * BALANCING MENTAL HEALTH AND TYPE 1 DIABETES
   
   Our May TypeOneNation Summit offered practical tips on managing mental health
   with type 1 diabetes from leading experts and community members.
   
   Read More about Balancing Mental Health and Type 1 Diabetes
   


 * INSULIN ACT TO HELP ACHIEVE INSULIN AFFORDABILITY
   
   The JDRF-supported INSULIN Act will build on years advocacy and make insulin
   more affordable for more people.
   
   Read More about INSULIN Act to Help Achieve Insulin Affordability
   


 * JDRF ADVOCATES, A VOICE FOR THE T1D COMMUNITY
   
   JDRF Advocates use the most powerful tools they have—their own personal
   stories—to raise awareness and power progress for the type 1 diabetes
   community.
   
   Read More about JDRF Advocates, A Voice for the T1D Community
   

Also of Interest:
 * Early Symptoms of Diabetes
 * The Importance of Advocacy
 * Curing Type 1 Diabetes

 * About
 * Careers
 * Privacy
 * Terms of Use
 * Copyright
 * Editorial Policy
 * Accessibilty
 * Contact
 * For Researchers

 * 
 * 
 * 
 * 
 * 




YOUR PRIVACY

We value your privacy. When you visit JDRF.org (and our family of websites), we
use cookies to process your personal data in order to customize content and
improve your site experience, provide social media features, analyze our
traffic, and personalize advertising. By choosing “I Agree”, you understand and
agree to JDRF’s Privacy Policy.

I Decline I Agree

  Accessibility
Open Save Later


SAVE FOR LATER

Email * Required Field.

Cancel Save Save

Notifications








Feedback